
Title:
Psychedelic drug
Text:
Hallucinogenic class of psychoactive drug
.mw-parser-output .hatnote{font-style:italic}.mw-parser-output div.hatnote{padding-left:1.6em;margin-bottom:0.5em}.mw-parser-output .hatnote i{font-style:normal}.mw-parser-output .hatnote+link+.hatnote{margin-top:-0.5em}"Psychedelic" redirects here. For other uses, see Psychedelic (disambiguation).
  Synthetic mescaline. Normally biosynthesized from peyote and some other cacti, mescaline was the first psychedelic compound to be extracted and isolated.[1]
Psychedelics are a class of hallucinogenic drugs whose primary effect is to trigger non-ordinary states of consciousness (known as psychedelic experiences or "trips").[2][3][4] This causes specific psychological, visual and auditory changes, and often a substantially altered state of consciousness.[5][6][3][7] The "classical" psychedelics, the psychedelics with the largest scientific and cultural influence, are mescaline, LSD, psilocybin, and DMT.[8][9][10][11]
Most psychedelic drugs fall into one of the three families of chemical compounds: tryptamines, phenethylamines, or lysergamides and many tend to act via serotonin 2A receptor agonism. When compounds bind to serotonin 5-HT2A receptors,[12] they modulate the activity of key circuits in the brain involved with sensory perception and cognition, however the exact nature of how psychedelics induce changes in perception and cognition via the 5-HT2A receptor is still unknown, although the fact that psychedelics reduce default mode network activity and increased connectivity between regions in the brain as a result is likely one of the most relevant pharmacological mechanisms underpinning the psychedelic experience,[13][14] particularly ego death.[15] The psychedelic experience is often compared to non-ordinary forms of consciousness such as those experienced in meditation,[16][3] mystical experiences,[17][7] and near-death experiences,[7] which also appear to be partially underpinned by altered default mode network activity.[18][19] The phenomenon of ego death is often described as a key feature of the psychedelic experience.[16][3][7]
Many psychedelic drugs are illegal worldwide under the UN conventions, with occasional exceptions for religious use or research contexts. Despite these controls, recreational use of psychedelics is common.[20][21] Legal barriers have made the scientific study of psychedelics more difficult. Research has been conducted, however, and studies show that psychedelics are physiologically safe and do not lead to addiction.[22][23] Studies conducted using psilocybin in a psychotherapeutic setting reveal that psychedelic drugs may assist with treating depression and alcohol addiction, and possibly also nicotine addiction.[24][25] Although further research is needed, existing results are showing that psychedelics may be useful for treating certain forms of psychopathology.[26][27][21]

Contents

1 Etymology and nomenclature
2 Examples
3 Uses

3.1 Traditional
3.2 Psychedelic therapy
3.3 Recreational
3.4 Microdosing


4 Pharmacology

4.1 Tryptamines
4.2 Phenethylamines
4.3 Lysergamides


5 Psychedelic experiences
6 Potential adverse effects
7 Potential therapeutic effects
8 Shamanic, spiritual and religious use
9 Surrounding culture
10 Legal status
11 See also

11.1 Categories


12 Notes
13 Further reading
14 External links



Etymology and nomenclature[edit]
  5-HT2A receptor
The term psychedelic was coined by the psychiatrist Humphrey Osmond during written correspondence with author Aldous Huxley and presented to the New York Academy of Sciences by Osmond in 1957.[28] It is irregularly[29] derived from the Greek words ψυχή psychḗ 'soul, mind' and δηλείν dēleín 'to manifest', with the intended meaning "mind manifesting," the implication being that psychedelics can develop unused potentials of the human mind.[30] The term was loathed by American ethnobotanist Richard Schultes but championed by American psychologist Timothy Leary.[31]
Aldous Huxley had suggested his own coinage phanerothyme (Greek phaneroein- "visible" and Greek thymos "soul", thus "visible soul") to Osmond in 1956.[32] Recently, the term entheogenic has come into use to denote the use of psychedelic drugs, as well as various other types of psychoactive substances, in a religious, spiritual, and mystical context.[33]
In 2004, David E. Nichols wrote the following about the nomenclature used for psychedelic drugs:

.mw-parser-output .templatequote{overflow:hidden;margin:1em 0;padding:0 40px}.mw-parser-output .templatequote .templatequotecite{line-height:1.5em;text-align:left;padding-left:1.6em;margin-top:0}Many different names have been proposed over the years for this drug class. The famous German toxicologist Louis Lewin used the name phantastica earlier in this century, and as we shall see later, such a descriptor is not so farfetched. The most popular names—hallucinogen, psychotomimetic, and psychedelic ("mind manifesting")—have often been used interchangeably. Hallucinogen is now, however, the most common designation in the scientific literature, although it is an inaccurate descriptor of the actual effects of these drugs. In the lay press, the term psychedelic is still the most popular and has held sway for nearly four decades. Most recently, there has been a movement in nonscientific circles to recognize the ability of these substances to provoke mystical experiences and evoke feelings of spiritual significance. Thus, the term entheogen, derived from the Greek word entheos, which means "god within", was introduced by Ruck et al. and has seen increasing use. This term suggests that these substances reveal or allow a connection to the "divine within". Although it seems unlikely that this name will ever be accepted in formal scientific circles, its use has dramatically increased in the popular media and on internet sites. Indeed, in much of the counterculture that uses these substances, entheogen has replaced psychedelic as the name of choice and we may expect to see this trend continue.[33]
Robin Carhart-Harris and Guy Goodwin write that the term psychedelic is preferable to hallucinogen for describing classical psychedelics because of the term hallucinogen's "arguably misleading emphasis on these compounds' hallucinogenic properties."[34]

Examples[edit]
  Doses of lysergic acid diethylamide (LSD)
Main article: List of psychedelic drugs
LSD (Lysergic acid diethylamide) is a derivative of lysergic acid, which is obtained from the hydrolysis of ergotamine. Ergotamine is an alkaloid found in the fungus claviceps purpurea, which primarily infects rye. LSD is both the prototypical psychedelic and the prototypical lysergamide. As a lysergamide, LSD contains both a tryptamine and phenethylamine group within its structure. As a result of containing a phenethylamine group LSD agonises dopamine receptors as well as serotonin receptors,[35] making it more energetic in effect in contrast to the more sedating effects of psilocin, which isn't a dopamine agonist.[36]
Psilocin (4-HO-DMT) is the dephosphorylated active metabolite of the indole alkaloid psilocybin and a substituted tryptamine, which is produced in over 200 species of fungi. Of the Classical psychedelics psilocybin has attracted the greatest academic interest regarding its ability to manifest mystical experiences.[37] Although all psychedelics are capable of doing so to variable degrees.
Mescaline (3,4,5-trimethoxyphenethylamine) is a phenthylamine alkaloid found in various species of cacti, the most well known being Peyote (Lophophora williamsii). Mescaline has effects comparable to those of LSD and psilocybin, Albeit with a greater emphasis on colors and patterns.[38]
DMT (N,N-dimethyltryptamine) is an indole alkaloid found in various species of plants. Traditionally it is consumed by tribes in South America in the form of ayahuasca. A brew is used that consists of DMT-containing plants as well as plants containing MAOIs, specifically harmaline, which allows DMT to be consumed orally without being rendered inactive by monoamine oxidase enzymes in the digestive system.[39] In the Western world DMT is more commonly consumed via the vaporisation of freebase DMT. Whereas Ayahuasca typically lasts for several hours, inhalation has an onset measured in seconds and has effects measured in minutes, being significantly more intense.[40] Particularly in vaporised form, DMT has the ability to cause users to enter a hallucinatory realm fully detached from reality, being typically characterised by hyperbolic geometry, and described as defying visual or verbal description.[41] Users have also reported encountering and communicating with entitites within this hallucinatory state.[42] DMT is the archeypal substituted tryptamine, being the structural scaffold of psilocybin and - to a lesser extent - the lysergamides.
2C-B (2,5-dimethoxy-4-bromophenethylamine) is a substituted phenthylamine first synthesised in 1974 by Alexander Shulgin.[43] 2C-B is both a psychedelic and a mild entactogen, with its psychedelic effects increasing and its entactogenic effects decreasing with dosage. 2C-B is the most well known compound in the 2C family, their general structure being discovered as a result of modifying the structure of mescaline.[43]
Uses[edit]
Traditional[edit]
Psychedelics have a long history of use in traditional medicine and traditional religion, for their perceived ability to promote physical and mental healing. In this context, they are often known as entheogens. Native American practitioners using mescaline-containing cacti (most notably peyote, San Pedro, and Peruvian torch) have reported success in treating alcoholism, and Mazatec practitioners routinely use psilocybin mushrooms for divination and healing.[citation needed] The psychoactive brew ayahuasca is used in Peru and other parts of South America for spiritual and physical healing as well as in religious festivals.[44]

Psychedelic therapy[edit]
Main article: Psychedelic therapy
Many of the currently known psychedelics are classified as having no accepted medical use in the United States.[45] However, in 2018 the United States Food and Drug Administration (FDA) granted breakthrough therapy designation for psilocybin-assisted therapy for treatment-resistant major depressive disorder.[46] In 2019, the FDA also granted breakthrough therapy designation for psilocybin therapy treating major depressive disorder more generally.[47][48]

Recreational[edit]
Further information: Recreational drug use § Hallucinogens
Recreational use of psychedelics is common.[20][21]

Microdosing[edit]
Main article: Psychedelic microdosing
Psychedelic microdosing is the practice of using sub-threshold doses (microdoses) of psychedelics in an attempt to improve creativity, boost physical energy level, emotional balance, increase performance on problems-solving tasks and to treat anxiety, depression and addiction.[49][50]  The practice of microdosing has become more widespread in the 21st century with more people claiming long-term benefits from the practice.[51][52]

Pharmacology[edit]
Psychedelics are 5-HT2A receptor agonists (serotonin 2A receptor agonists).[53][54]

  N,N-DMT
Tryptamines[edit]
Tryptamine, along with other trace amines, is found in the central nervous system of mammals. It is hypothesized to play a role as a neuromodulator on classical monoamine neurotransmitters, such as dopamine, serotonin, and norepinephrine (epinephrine). Tryptamine acts as a non-selective serotonin receptor agonist to activate serotonin receptors, and a serotonin–norepinephrine–dopamine releasing agent (SNDRA) to release more monoamine neurotransmitter, with a preference for evoking serotonin and dopamine release over norepinephrine (epinephrine) release.[55][56][57] Psychedelic tryptamines found in nature include psilocin, DMT, 5-MeO-DMT, and tryptamines that have been synthesized in the laboratory include 4-HO-MET and 5-MeO-DALT.[58]

  Mescaline
Phenethylamines[edit]
Phenethylamine is also a trace amine but to a lesser extent acts as a neurotransmitter in the human central nervous system (CNS). Phenethylamine instead regulates monoamine neurotransmission by binding to trace amine-associated receptor 1 (TAAR1), which plays a significant role in regulating neurotransmission in dopamine, norepinephrine, and serotonin neurons in the CNS and inhibiting vesicular monoamine transporter 2 (VMAT2) in monoamine neurons.[59][60] When VMAT2 is inhibited monoamine neurotransmitters such as dopamine cannot be released into the synapse via typical release mechanisms.[61] Mescaline is a naturally occurring psychedelic protoalkaloid of the substituted phenethylamine class.

Lysergamides[edit]
  Lysergic acid diethylamide (LSD)
Amides of lysergic acid are collectively known as lysergamides, and include a number of compounds with potent agonist and/or antagonist activity at various serotonin and dopamine receptors. LSD is one of many lysergamides. A wide range of lysergamides have emerged in recent years, inspired by existing scientific literature. Others, have appeared from chemical research.[62] 1P-LSD is a derivative and functional analogue of LSD and a homologue of ALD-52. It modifies the LSD molecule by adding a propionyl group to the nitrogen molecule of LSD's indole.[63]

Psychedelic experiences[edit]
Main article: Psychedelic experience
Although several attempts have been made, starting in the 19th and 20th centuries, to define common phenomenological structures of the effects produced by classic psychedelics, a universally accepted taxonomy does not yet exist.[64][65] At lower doses, features of psychedelic experiences include sensory alterations, such as the warping of surfaces, shape suggestibility, and color variations. Users often report intense colors that they have not previously experienced, and repetitive geometric shapes are common. Higher doses often cause intense and fundamental alterations of sensory perception, such as synesthesia or the experience of additional spatial or temporal dimensions.[66]
Classic psychedelics are considered to be those found in nature like psilocybin, DMT, mescaline, and LSD which is derived from naturally occurring ergotamine, and non-classic psychedelics are considered to be newer analogs and derivatives of pharmacophore lysergamides, tryptamine, and phenethylamine structures like 2C-B.  Many of these psychedelics cause remarkably similar effects, despite their different chemical structure. However, many users report that the three major families have subjectively different qualities in the "feel" of the experience, which are difficult to describe. Some compounds, such as 2C-B, have extremely tight "dose curves", meaning the difference in dose between a non-event and an overwhelming disconnection from reality can be very slight. There can also be very substantial differences between the drugs; for instance, 5-MeO-DMT rarely produces the visual effects typical of other psychedelics.[citation needed] Tryptamines are well documented to cause classic psychedelic states, such as increased empathy, visual distorsions (drifting, morphing, breathing, melting of various surfaces and objects), auditory hallucinations, ego dissolution or ego death with high enough dose, mystical and spiritual experiences, closed eye hallucinations and complete detachment from reality with a high enough dose.[67]

Potential adverse effects[edit]
See also: Bad trip and Trip sitter
Despite the contrary perception of much of the public, psychedelic drugs are not addictive and are physiologically safe.[22][23][24] As of 2016, there have been no known deaths due to overdose of LSD, psilocybin, or mescaline.[24]
Risks do exist during an unsupervised psychedelic experience, however; Ira Byock wrote in 2018 in the Journal of Palliative Medicine that psilocybin is safe when administered to a properly screened patient and supervised by a qualified professional with appropriate set and setting. However, he called for an "abundance of caution" because in the absence of these conditions a range of negative reactions is possible, including "fear, a prolonged sense of dread, or full panic." He notes that driving or even walking in public can be dangerous during a psychedelic experience because of impaired hand-eye coordination and fine motor control.[68] In some cases, individuals taking psychedelics have performed dangerous or fatal acts because they believed they possessed superhuman powers.[24]
The usage of most psychedelics entails some risk of eliciting flashbacks of the drug experience even after the effects have worn off, albeit rarely.[69] HPPD or other after-effects may also occur. Psilocybin-induced states of mind share features with states experienced in psychosis, and while a causal relationship between psilocybin and the onset of psychosis has not been established as of 2011, researchers have called for investigation of the relationship.[69] A population study on associations between psychedelic use and mental illness published in 2013 found no evidence that psychedelic use was associated with increased prevalence of any mental illness.[70]

Potential therapeutic effects[edit]
Further information: Psychedelic therapy
  Psilocybin session at Johns Hopkins
Psychedelic substances which may have therapeutic uses include psilocybin, LSD, and mescaline.[27] During the 1950s and 1960s, lack of informed consent in some scientific trials on psychedelics led to significant, long-lasting harm to some participants.[27] Since then, research regarding the effectiveness of psychedelic therapy has been conducted under strict ethical guidelines, with fully informed consent and a pre-screening to avoid people with psychosis taking part.[27] Although the history behind these substances has hindered research into their potential medicinal value, scientists are now able to conduct studies and renew research that was halted in the 1970s. Some research has shown that these substances have helped people with such mental disorders as obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), alcoholism, depression, and cluster headaches.[21]
It has long been known that psychedelics promote neurite growth and synaptic plasticity.[71][72][73] There is evidence that psychedelics induce molecular and cellular adaptations related to neuroplasticity and that these could potentially underlie therapeutic benefits.[74] Psychedelics have also been shown to have potent anti-inflammatory activity and therapeutic effects in animal models of inflammatory diseases including asthma,[75] and cardiovascular disease and diabetes.[76]

Shamanic, spiritual and religious use[edit]
  Preparation of Ayahuasca, Province of Pastaza, Ecuador.
This section needs expansion. You can help by adding to it.  (August 2021)
A number of frequently mentioned or traditional psychedelics such as Ayahuasca (which contains DMT), San Pedro (which contains mescaline), Psilocybe mushrooms (which contain psilocin/psilocybin) and Tabernanthe iboga (which contains the unique psychedelic ibogaine) all have a long and extensive history of spiritual, shamanic and traditional usage by indigenous peoples in various world regions, particularly in Latin America but in the case of iboga, Gabon, Africa.[citation needed]
Different countries have come to be associated with particular psychedelic entheogens such as ayahuasca's spiritual importance in regions of Peru near the Amazon Basin[77] and the entheogenic use of psilocybe mushrooms by the native Mazatec people of Oaxaca, Mexico.[citation needed]

Surrounding culture[edit]
  Psychedelic rock band Jefferson Airplane in 1967
Main article: Psychedelia
Psychedelic culture includes manifestations such as psychedelic music,[78] psychedelic art,[79] psychedelic literature,[80] psychedelic film,[81] and psychedelic festivals.[82] Examples of psychedelic music would be rock bands like the Grateful Dead and Jefferson Airplane. Many psychedelic bands and elements of the psychedelic subculture originated in San Francisco during the mid to late 1960s[83]

Legal status[edit]
See also: Legal status of psilocybin mushrooms, Psilocybin decriminalization in the United States, and Legal status of ayahuasca by country
Many psychedelics are classified under Schedule I of the United Nations Convention on Psychotropic Substances of 1971 as drugs with the greatest potential to cause harm and no acceptable medical uses.[84] In addition, many countries have analogue laws; for example, in the United States, the Federal Analogue Act of 1986 automatically forbids any drugs sharing similar chemical structures or chemical formulas to illicit or prohibited substances if sold for human consumption.[citation needed]

See also[edit]
.mw-parser-output .div-col{margin-top:0.3em;column-width:30em}.mw-parser-output .div-col-small{font-size:90%}.mw-parser-output .div-col-rules{column-rule:1px solid #aaa}.mw-parser-output .div-col dl,.mw-parser-output .div-col ol,.mw-parser-output .div-col ul{margin-top:0}.mw-parser-output .div-col li,.mw-parser-output .div-col dd{page-break-inside:avoid;break-inside:avoid-column}
Aztec use of entheogens
Bwiti
Cognitive liberty
Concord Prison Experiment
Designer Drugs
Dissociative drug
Drug harmfulness
Entheogenic drugs and the archaeological record
Entheogenics and the Maya
Hallucinogenic fish
Hallucinogenic plants in Chinese herbals
Hamilton's Pharmacopeia
History of lysergic acid diethylamide
Ibogaine
List of psychedelic plants
Marsh Chapel Experiment
Morning glory
Mystical psychosis
PiHKAL
Psychedelia – Film about the history of psychedelic drugs
Psychedelics in problem-solving experiment
Serotonergic psychedelic
Tabernanthe iboga
TiHKAL
Research chemical
List of psychedelic drugs
List of designer drugs

Categories[edit]
  Psychedelic drugs  Drug classes defined by psychological effects
  Drugs by psychological effects
  Psychoactive drugs
Notes[edit]
.mw-parser-output .reflist{font-size:90%;margin-bottom:0.5em;list-style-type:decimal}.mw-parser-output .reflist .references{font-size:100%;margin-bottom:0;list-style-type:inherit}.mw-parser-output .reflist-columns-2{column-width:30em}.mw-parser-output .reflist-columns-3{column-width:25em}.mw-parser-output .reflist-columns{margin-top:0.3em}.mw-parser-output .reflist-columns ol{margin-top:0}.mw-parser-output .reflist-columns li{page-break-inside:avoid;break-inside:avoid-column}.mw-parser-output .reflist-upper-alpha{list-style-type:upper-alpha}.mw-parser-output .reflist-upper-roman{list-style-type:upper-roman}.mw-parser-output .reflist-lower-alpha{list-style-type:lower-alpha}.mw-parser-output .reflist-lower-greek{list-style-type:lower-greek}.mw-parser-output .reflist-lower-roman{list-style-type:lower-roman}

^ .mw-parser-output cite.citation{font-style:inherit;word-wrap:break-word}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .citation:target{background-color:rgba(0,127,255,0.133)}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .cs1-ws-icon a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg")right 0.1em center/12px no-repeat}.mw-parser-output .cs1-code{color:inherit;background:inherit;border:none;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;color:#d33}.mw-parser-output .cs1-visible-error{color:#d33}.mw-parser-output .cs1-maint{display:none;color:#3a3;margin-left:0.3em}.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}"Peyote San Pedro Cactus – Shamanic Sacraments". D.M.Taylor.

^ Aghajanian, G (August 1999). "Serotonin and Hallucinogens". Neuropsychopharmacology. 21 (2): 16S–23S. doi:10.1016/S0893-133X(98)00135-3. PMID 10432484.

^ a b c d Millière, Raphaël; Carhart-Harris, Robin L.; Roseman, Leor; Trautwein, Fynn-Mathis; Berkovich-Ohana, Aviva (2018). "Psychedelics, Meditation, and Self-Consciousness". Frontiers in Psychology. 9: 1475. doi:10.3389/fpsyg.2018.01475. PMC 6137697. PMID 30245648.

^ Pollan, Michael (2018). How to Change Your Mind: What the New Science of Psychedelics Teaches Us About Consciousness, Dying, Addiction, Depression, and Transcendence

^ Leary, Timothy; Metzner, Ralph (1964). The Psychedelic Experience: A Manual Based on The Tibetan Book of the Dead

^ McKenna, Terence (1989). True Hallucinations: Being an Account of the Author's Extraordinary Adventures in the Devil's Paradise

^ a b c d Timmermann, Christopher; Roseman, Leor; Williams, Luke; Erritzoe, David; Martial, Charlotte; Cassol, Héléna; Laureys, Steven; Nutt, David; Carhart-Harris, Robin (2018). "DMT Models the Near-Death Experience". Frontiers in Psychology. 9: 1424. doi:10.3389/fpsyg.2018.01424. PMC 6107838. PMID 30174629.

^ Leary, Timothy; Metzner, Ralph (1964). The Psychedelic Experience: A Manual Based on The Tibetan Book of the Dead

^ McKenna, Terence (1992). Food of the Gods: The Search for the Original Tree of Knowledge A Radical History of Plants, Drugs, and Human Evolution

^ W. Davis (1996), One River: Explorations and Discoveries in the Amazon Rain Forest. New York, Simon and Schuster, Inc. p. 120.

^ Pollan, Michael (2018). How to Change Your Mind: What the New Science of Psychedelics Teaches Us About Consciousness, Dying, Addiction, Depression, and Transcendence

^ Basic neurochemistry : molecular, cellular and medical aspects. Siegel, George J. (7th ed.). Amsterdam. 11 November 2005. ISBN 978-0-08-047207-2. OCLC 123438340.{{cite book}}:  CS1 maint: others (link)

^ Smigielski, Lukasz; Scheidegger, Milan; Kometer, Michael; Vollenweider, Franz X. (August 2019). "Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects". NeuroImage. 196: 207–215. doi:10.1016/j.neuroimage.2019.04.009. PMID 30965131. S2CID 102487343.

^ Palhano-Fontes, Fernanda; Andrade, Katia C.; Tofoli, Luis F.; Santos, Antonio C.; Crippa, Jose Alexandre S.; Hallak, Jaime E. C.; Ribeiro, Sidarta; Araujo, Draulio B. de (2015-02-18). "The Psychedelic State Induced by Ayahuasca Modulates the Activity and Connectivity of the Default Mode Network". PLOS ONE. 10 (2): e0118143. Bibcode:2015PLoSO..1018143P. doi:10.1371/journal.pone.0118143. ISSN 1932-6203. PMC 4334486. PMID 25693169.

^ Tagliazucchi, Enzo; Roseman, Leor; Kaelen, Mendel; Orban, Csaba; Muthukumaraswamy, Suresh; Murphy, Kevin; Laufs, Helmut; Leech, Robert; McGonigle, John; Crossley, Nicolas; Bullmore, Edward (2016). "Increased Global Functional Connectivity Correlates with LSD-Induced Ego Dissolution". Current Biology. 26 (8): 1043–1050. doi:10.1016/j.cub.2016.02.010. PMID 27085214. S2CID 3865696.

^ a b Letheby, Chris; Gerrans, Philip (2017). "Self unbound: ego dissolution in psychedelic experience". Neuroscience of Consciousness. 3 (1): nix016. doi:10.1093/nc/nix016. PMC 6007152. PMID 30042848. The connection with findings about PCC deactivation in ‘effortless awareness’ meditation is obvious, and bolstered by the finding that acute ayahuasca intoxication increases mindfulness-related capacities.

^ R. R. Griffiths; W. A. Richards; U. McCann; R. Jesse (7 July 2006). "Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance". Psychopharmacology. 187 (3): 268–283. doi:10.1007/s00213-006-0457-5. PMID 16826400. S2CID 7845214.

^ Brewer, Judson A.; Worhunsky, Patrick D.; Gray, Jeremy R.; Tang, Yi-Yuan; Weber, Jochen; Kober, Hedy (2011-12-13). "Meditation experience is associated with differences in default mode network activity and connectivity". Proceedings of the National Academy of Sciences. 108 (50): 20254–20259. Bibcode:2011PNAS..10820254B. doi:10.1073/pnas.1112029108. PMC 3250176. PMID 22114193.

^ Rim, James I.; Ojeda, Jesse Caleb; Svob, Connie; Kayser, Jürgen; Drews, Elisa; Kim, Youkyung; Tenke, Craig E.; Skipper, Jamie; Weissman, Myrna M. (2019). "Current Understanding of Religion, Spirituality, and Their Neurobiological Correlates". Harvard Review of Psychiatry. 27 (5): 303–316. doi:10.1097/HRP.0000000000000232. ISSN 1465-7309. PMC 7195862. PMID 31490186.

^ a b Krebs, Teri S; Johansen, Pål-Ørjan (28 March 2013). "Over 30 million psychedelic users in the United States". F1000Research. 2: 98. doi:10.12688/f1000research.2-98.v1. PMC 3917651. PMID 24627778.

^ a b c d Garcia-Romeu, Albert; Kersgaard, Brennan; Addy, Peter H. (August 2016). "Clinical applications of hallucinogens: A review". Experimental and Clinical Psychopharmacology. 24 (4): 229–268. doi:10.1037/pha0000084. PMC 5001686. PMID 27454674.

^ a b Le Dain, Gerald (1971). The Non-medical Use of Drugs: Interim Report of the Canadian Government's Commission of Inquiry. p. 106. Physical dependence does not develop to LSD

^ a b Lüscher, Christian; Ungless, Mark A. (14 November 2006). "The Mechanistic Classification of Addictive Drugs". PLOS Medicine. 3 (11): e437. doi:10.1371/journal.pmed.0030437. PMC 1635740. PMID 17105338.

^ a b c d Nichols, D. E. (3 February 2016). "Psychedelics". Pharmacological Reviews. 68 (2): 264–355. doi:10.1124/pr.115.011478. PMC 4813425. PMID 26841800.

^ Rich Haridy (24 October 2018). "Psychedelic psilocybin therapy for depression granted Breakthrough Therapy status by FDA". newatlas.com. Retrieved 2019-09-27.

^ Friedman, Harris (2006). "The Renewal of Psychedelic Research: Implications for Humanistic and Transpersonal Psychology". The Humanistic Psychologist. 34 (1): 39–58. doi:10.1207/s15473333thp3401_5. ISSN 1547-3333.

^ a b c d Tupper, Kenneth W.; Wood, Evan; Yensen, Richard; Johnson, Matthew W. (2015-10-06). "Psychedelic medicine: a re-emerging therapeutic paradigm". CMAJ : Canadian Medical Association Journal. 187 (14): 1054–1059. doi:10.1503/cmaj.141124. ISSN 0820-3946. PMC 4592297. PMID 26350908.

^ Tanne, Janice Hopkins (2004). "Humphrey Osmond". BMJ. 328 (7441): 713. doi:10.1136/bmj.328.7441.713. PMC 381240.

^ Oxford English Dictionary, 3rd edition, September 2007, s.v., Etymology

^ A. Weil, W. Rosen. (1993), From Chocolate To Morphine: Everything You Need To Know About Mind-Altering Drugs. New York, Houghton Mifflin Company. p. 93

^ W. Davis (1996), "One River: Explorations and Discoveries in the Amazon Rain Forest". New York, Simon and Schuster, Inc. p. 120.

^ iia700700.us.archive.org

^ a b Nichols DE (February 2004). "Hallucinogens". Pharmacology & Therapeutics. 101 (2): 131–81. doi:10.1016/j.pharmthera.2003.11.002. PMID 14761703.

^ Carhart-Harris, Robin; Guy, Goodwin (2017). "The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future". Neuropsychopharmacology. 42 (11): 2105–2113. doi:10.1038/npp.2017.84. PMC 5603818. PMID 28443617.

^ Creese, Ian; Burt, David R.; Snyder, Solomon H. (1975-12-01). "The dopamine receptor: Differential binding of d-LSD and related agents to agonist and antagonist states". Life Sciences. 17 (11): 1715–1719. doi:10.1016/0024-3205(75)90118-6. ISSN 0024-3205. PMID 1207384.

^ Passie, Torsten; Seifert, Juergen; Schneider, Udo; Emrich, Hinderk M. (October 2002). "The pharmacology of psilocybin". Addiction Biology. 7 (4): 357–364. doi:10.1080/1355621021000005937. PMID 14578010. S2CID 12656091.

^ Griffiths, R. R.; Richards, W. A.; McCann, U.; Jesse, R. (August 2006). "Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance". Psychopharmacology. 187 (3): 268–283. doi:10.1007/s00213-006-0457-5. ISSN 0033-3158. PMID 16826400. S2CID 7845214.

^ Freye, E. (2009). Pharmacology and abuse of cocaine, amphetamines, ecstasy and related designer drugs : a comprehensive review on their mode of action, treatment of abuse and intoxication. Dordrecht: Springer. ISBN 978-90-481-2448-0. OCLC 489218895.

^ Riba, Jordi; Valle, Marta; Urbano, Gloria; Yritia, Mercedes; Morte, Adelaida; Barbanoj, Manel J. (July 2003). "Human Pharmacology of Ayahuasca: Subjective and Cardiovascular Effects, Monoamine Metabolite Excretion, and Pharmacokinetics". Journal of Pharmacology and Experimental Therapeutics. 306 (1): 73–83. doi:10.1124/jpet.103.049882. ISSN 0022-3565. PMID 12660312. S2CID 6147566.

^ Haroz, Rachel; Greenberg, Michael I. (November 2005). "Emerging drugs of abuse". The Medical Clinics of North America. 89 (6): 1259–1276. doi:10.1016/j.mcna.2005.06.008. ISSN 0025-7125. PMID 16227062.

^ Strassman, Ruck J.; Qualls, Clifford R.; Uhlenhuth, Eberhard H.; Kellner, Robert (1994-02-01). "Dose-Response Study of N,N-Dimethyltryptamine in Humans: II. Subjective Effects and Preliminary Results of a New Rating Scale". Archives of General Psychiatry. 51 (2): 98–108. doi:10.1001/archpsyc.1994.03950020022002. ISSN 0003-990X. PMID 8297217.

^ Davis, Alan K; Clifton, John M; Weaver, Eric G; Hurwitz, Ethan S; Johnson, Matthew W; Griffiths, Roland R (September 2020). "Survey of entity encounter experiences occasioned by inhaled N,N -dimethyltryptamine: Phenomenology, interpretation, and enduring effects". Journal of Psychopharmacology. 34 (9): 1008–1020. doi:10.1177/0269881120916143. ISSN 0269-8811. PMID 32345112.

^ a b Shulgin, Alexander T. (1991). Pihkal : a chemical love story. Ann Shulgin. Berkeley, CA: Transform Press. ISBN 0-9630096-0-5. OCLC 25627628.

^ Ismael Eduardo Apud Peláez. (2020). Ayahuasca: Between Cognition and Culture. Publicacions Universitat Rovira i Virgili. ISBN 978-84-8424-834-7. OCLC 1229544084.

^ Anderson, Brian (2006). "Psychedelic Psychotherapy The Ethics of Medicine for the Soul" (PDF). Penn Bioethics Journal. 2: 9–12.

^ "COMPASS Pathways Receives FDA Breakthrough Therapy Designation for Psilocybin Therapy for Treatment-resistant Depression – COMPASS". compasspathways.com. Retrieved 2018-12-03.

^ "FDA grants Breakthrough Therapy Designation to Usona Institute's psilocybin program for major depressive disorder". www.businesswire.com. 2019-11-22. Retrieved 2019-11-25.

^ "How to prepare for a PSYCHEDELIC TRIP?". psychedelicsofficial.com. 2019-11-22. Retrieved 2019-11-25.

^ Fadiman J (2016-01-01). "Microdose research: without approvals, control groups, double blinds, staff or funding". Psychedelic Press. XV.

^ Brodwin E (30 January 2017). "The truth about 'microdosing,' which involves taking tiny amounts of psychedelics like LSD". Business Insider. Retrieved 19 April 2017.

^ Dahl H (7 July 2015). "A Brief History of LSD in the Twenty-First Century". Psychedelic Press UK. Retrieved 19 April 2017.

^ Webb M, Copes H, Hendricks PS (August 2019). "Narrative identity, rationality, and microdosing classic psychedelics". The International Journal on Drug Policy. 70: 33–39. doi:10.1016/j.drugpo.2019.04.013. PMID 31071597. S2CID 149445841.

^ Aghajanian, G (August 1999). "Serotonin and Hallucinogens". Neuropsychopharmacology. 21 (2): 16S–23S. doi:10.1016/S0893-133X(98)00135-3. PMID 10432484.

^ "Crystal Structure of LSD and 5-HT2AR Part 2: Binding Details and Future Psychedelic Research Paths". Psychedelic Science Review. 2020-10-05. Retrieved 2021-02-12.

^ Wölfel, Reinhard; Graefe, Karl-Heinz (February 1992). "Evidence for various tryptamines and related compounds acting as substrates of the platelet 5-hydroxytryptamine transporter". Naunyn-Schmiedeberg's Archives of Pharmacology. 345 (2): 129–136. doi:10.1007/BF00165727. ISSN 0028-1298. PMID 1570019. S2CID 2984583.

^ Shimazu, Seiichiro; Miklya, Ildikó (May 2004). "Pharmacological studies with endogenous enhancer substances: β-phenylethylamine, tryptamine, and their synthetic derivatives". Progress in Neuro-Psychopharmacology and Biological Psychiatry. 28 (3): 421–427. doi:10.1016/j.pnpbp.2003.11.016. PMID 15093948. S2CID 37564231.

^ Blough, Bruce E.; Landavazo, Antonio; Partilla, John S.; Baumann, Michael H.; Decker, Ann M.; Page, Kevin M.; Rothman, Richard B. (2014-06-12). "Hybrid Dopamine Uptake Blocker–Serotonin Releaser Ligands: A New Twist on Transporter-Focused Therapeutics". ACS Medicinal Chemistry Letters. 5 (6): 623–627. doi:10.1021/ml500113s. ISSN 1948-5875. PMC 4060932. PMID 24944732.

^ Shulgin, Alexander T. (Alexander Theodore) (1997). Tihkal : the continuation. Shulgin, Ann. (1st ed.). Berkeley, CA: Transform Press. ISBN 0-9630096-9-9. OCLC 38503252.

^ Miller, Gregory M. (2010-12-16). "The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity". Journal of Neurochemistry. 116 (2): 164–176. doi:10.1111/j.1471-4159.2010.07109.x. ISSN 0022-3042. PMC 3005101. PMID 21073468.

^ Grandy, Gina (2020-04-23). "Guest editorial". Gender in Management. 35 (3): 257–260. doi:10.1108/GM-05-2020-238. ISSN 1754-2413.

^ Little, Karley Y.; Krolewski, David M.; Zhang, Lian; Cassin, Bader J. (January 2003). "Loss of Striatal Vesicular Monoamine Transporter Protein (VMAT2) in Human Cocaine Users". American Journal of Psychiatry. 160 (1): 47–55. doi:10.1176/appi.ajp.160.1.47. ISSN 0002-953X. PMID 12505801.

^ Brandt, Simon D.; Kavanagh, Pierce V.; Westphal, Folker; Stratford, Alexander; Odland, Anna U.; Klein, Adam K.; Dowling, Geraldine; Dempster, Nicola M.; Wallach, Jason; Passie, Torsten; Halberstadt, Adam L. (2020-04-20). "Return of the lysergamides. Part VI: Analytical and behavioural characterization of 1‐cyclopropanoyl‐ d ‐lysergic acid diethylamide (1CP‐LSD)". Drug Testing and Analysis. 12 (6): 812–826. doi:10.1002/dta.2789. ISSN 1942-7603. PMID 32180350. S2CID 212738912.

^ Grumann, Christina; Henkel, Kerstin; Brandt, Simon D.; Stratford, Alexander; Passie, Torsten; Auwärter, Volker (2020). "Pharmacokinetics and subjective effects of 1P-LSD in humans after oral and intravenous administration". Drug Testing and Analysis. 12 (8): 1144–1153. doi:10.1002/dta.2821. ISSN 1942-7611. PMID 32415750.

^ Preller, Katrin H.; Vollenweider, Franz X. (2016). "Phenomenology, Structure, and Dynamic of Psychedelic States".  In Adam L. Halberstadt; Franz X. Vollenweider; David E. Nichols (eds.). Behavioral Neurobiology of Psychedelic Drugs. Current Topics in Behavioral Neurosciences. Vol. 36. Berlin, Heidelberg: Springer Berlin Heidelberg. pp. 221–256. doi:10.1007/7854_2016_459. ISBN 978-3-662-55878-2. PMID 28025814.

^ Swanson, Link R. (2018-03-02). "Unifying Theories of Psychedelic Drug Effects". Frontiers in Pharmacology. 9: 172. doi:10.3389/fphar.2018.00172. ISSN 1663-9812. PMC 5853825. PMID 29568270.

^ Luke, David (28 November 2013). "Rock Art or Rorschach: Is there More to Entoptics than Meets the Eye?". Time and Mind. 3 (1): 9–28. doi:10.2752/175169710x12549020810371. S2CID 144948636.

^ Berry, Mark D. (July 2004). "Mammalian central nervous system trace amines. Pharmacologic amphetamines, physiologic neuromodulators". Journal of Neurochemistry. 90 (2): 257–271. doi:10.1111/j.1471-4159.2004.02501.x. ISSN 0022-3042. PMID 15228583. S2CID 12126296.

^ Byock, Ira (2018). "Taking Psychedelics Seriously". Journal of Palliative Medicine. 21 (4): 417–421. doi:10.1089/jpm.2017.0684. PMC 5867510. PMID 29356590.

^ a b van Amsterdam, Jan; Opperhuizen, Antoon; van den Brink, Wim (2011). "Harm potential of magic mushroom use: A review". Regulatory Toxicology and Pharmacology. 59 (3): 423–429. doi:10.1016/j.yrtph.2011.01.006. PMID 21256914.

^ Krebs, Teri S.; Johansen, Pål-Ørjan; Lu, Lin (19 August 2013). "Psychedelics and Mental Health: A Population Study". PLOS ONE. 8 (8): e63972. Bibcode:2013PLoSO...863972K. doi:10.1371/journal.pone.0063972. PMC 3747247. PMID 23976938.

^ Jones, K.A.; Srivastave, D.P.; Allen, J.A.; Roth, B.L.; Penzes, P. (2009). "Psychedelics Promote Structural and Functional Neural Plasticity". Proc Natl Acad Sci U S A. 106 (46): 19575–19580. doi:10.1073/pnas.0905884106. PMC 2780750. PMID 19889983.

^ Yoshida, H.; Kanamaru, C.; Ohtani, A.; Senzaki, K.; Shiga, T. (2011). "Subtype specific roles of serotonin receptors in the spine formation of cortical neurons in vitro". Neurosci Res. 71 (3): 311–314. doi:10.1016/j.neures.2011.07.1824. hdl:2241/114624. PMID 21802453. S2CID 14178672.

^ Ly, Calvin; Greb, Alexandra C.; Cameron, Lindsay P.; Wong, Jonathan M.; Barragan, Eden V.; Wilson, Paige C.; Burbach, Kyle F.; Soltanzadeh Zarandi, Sina; Sood, Alexander; Paddy, Michael R.; Duim, Whitney C.; Dennis, Megan Y.; McAllister, A. Kimberley; Ori-McKenney, Kassandra M.; Gray, John A.; Olson, David E. (June 2018). "Psychedelics Promote Structural and Functional Neural Plasticity". Cell Reports. 23 (11): 3170–3182. doi:10.1016/j.celrep.2018.05.022. PMC 6082376. PMID 29898390.

^ de Vos, Cato M. H.; Mason, Natasha L.; Kuypers, Kim P. C. (2021). "Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics". Frontiers in Psychiatry. 12: 1575. doi:10.3389/fpsyt.2021.724606. ISSN 1664-0640. PMC 8461007. PMID 34566723.

^ Nau, F.; Miller, J.; Saravia, J.; Ahlert, T.; Yu, B.; Happel, K.I; Cormier, S.A; Nichols, C.D. (2015). "Serotonin 5-HT₂ receptor activation prevents allergic asthma in a mouse model". American Journal of Physiology. Lung Cellular and Molecular Physiology. 308 (2): 191–198. doi:10.1152/ajplung.00138.2013. PMC 4338939. PMID 25416380.

^ Flanagan, T.W.; Sebastian, M.N.; Battaglia, D.M.; Foster, T.P.; Maillet, E.L.; Nichols, C.D. (2019). "Activation of 5-HT2 Receptors Reduces Inflammation in Vascular Tissue and Cholesterol Levels in High-Fat Diet-Fed Apolipoprotein E Knockout Mice". Sci. Rep. 9 (1): 13444–198. Bibcode:2019NatSR...913444F. doi:10.1038/s41598-019-49987-0. PMC 6748996. PMID 31530895.

^ "Overviews Shamanism – On the Origin of Ayahuasca". Ayahuasca.com. 2008. Retrieved 2013-04-27.

^ Hicks, Michael (15 January 2000). Sixties Rock: Garage, Psychedelic, and Other Satisfactions. Chicago, IL: University of Illinois Press. pp. 63–64. ISBN 0-252-06915-3.

^ Krippner, Stanley (2017). "Ecstatic Landscapes: The Manifestation of Psychedelic Art". Journal of Humanistic Psychology. 57 (4): 415–435. doi:10.1177/0022167816671579. S2CID 151517152.

^ Dickins, Robert (2013). "Preparing the Gaia connection: An ecological exposition of psychedelic literature 1954-1963". European Journal of Ecopsychology. 4: 9–18. CiteSeerX 10.1.1.854.6673. Retrieved 7 January 2021.

^ Gallagher, Mark (2004). "Tripped Out: The Psychedelic Film and Masculinity". Quarterly Review of Film and Video. 21 (3): 161–171. doi:10.1080/10509200490437817. S2CID 191583864.

^ St John, Graham. "Neotrance and the Psychedelic Festival." Dancecult: Journal of Electronic Dance Music Culture, 1(1) (2009).

^ Hirschfelder, Adam (Jan 14, 2016). "The Trips Festival explained". Experiments in Environment: The Halprin Workshops, 1966-1971.

^ Rucker, James J. H. (2015). "Psychedelic drugs should be legally reclassified so that researchers can investigate their therapeutic potential". British Medical Journal. 350: h2902. doi:10.1136/bmj.h2902. PMID 26014506. S2CID 46510541.


Further reading[edit]
Echard, William (2017). Psychedelic Popular Music: A History through Musical Topic Theory. Bloomington, IN: Indiana University Press. doi:10.2307/j.ctt1zxxzgx. ISBN 978-0253026453.
Halberstadt, Adam L.; Franz X. Vollenweider; David E. Nichols, eds. (2018). Behavioral Neurobiology of Psychedelic Drugs. Current Topics in Behavioral Neurosciences. Vol. 36. Berlin, Heidelberg: Springer. ISBN 978-3-662-55878-2.
Jay, Mike (2019). Mescaline: A Global History of the First Psychedelic. New Haven, CT: Yale University Press. doi:10.2307/j.ctvgc61q9. ISBN 9780300257502.
Letheby, Chris (2021). Philosophy of Psychedelics. Oxford: Oxford University Press. doi:10.1093/med/9780198843122.001.0001. ISBN 978-0-19-884312-2.
Richards, William A. (2016). Sacred Knowledge: Psychedelics and Religious Experiences. New York: Columbia University Press. ISBN 978-0-231-54091-9.
Siff, Stephen (2015). Acid Hype: American News Media and the Psychedelic Experience. Champaign, Illinois: University of Illinois Press. ISBN 978-0-252-09723-2.
Winstock, Ar; Timmerman, C; Davies, E; Maier, Lj; Zhuparris, A; Ferris, Ja; Barratt, Mj; Kuypers, Kpc (2021). Global Drug Survey (GDS) 2020 Psychedelics Key Findings Report.
External links[edit]
Psychedelic Timeline by Tom Frame. Psychedelic Times.

PsychonautWiki Community-driven online encyclopedia.


Wikiquote has quotations related to: Psychedelics




Wikimedia Commons has media related to Psychedelics.

.mw-parser-output .navbox{box-sizing:border-box;border:1px solid #a2a9b1;width:100%;clear:both;font-size:88%;text-align:center;padding:1px;margin:1em auto 0}.mw-parser-output .navbox .navbox{margin-top:0}.mw-parser-output .navbox+.navbox,.mw-parser-output .navbox+.navbox-styles+.navbox{margin-top:-1px}.mw-parser-output .navbox-inner,.mw-parser-output .navbox-subgroup{width:100%}.mw-parser-output .navbox-group,.mw-parser-output .navbox-title,.mw-parser-output .navbox-abovebelow{padding:0.25em 1em;line-height:1.5em;text-align:center}.mw-parser-output .navbox-group{white-space:nowrap;text-align:right}.mw-parser-output .navbox,.mw-parser-output .navbox-subgroup{background-color:#fdfdfd}.mw-parser-output .navbox-list{line-height:1.5em;border-color:#fdfdfd}.mw-parser-output .navbox-list-with-group{text-align:left;border-left-width:2px;border-left-style:solid}.mw-parser-output tr+tr>.navbox-abovebelow,.mw-parser-output tr+tr>.navbox-group,.mw-parser-output tr+tr>.navbox-image,.mw-parser-output tr+tr>.navbox-list{border-top:2px solid #fdfdfd}.mw-parser-output .navbox-title{background-color:#ccf}.mw-parser-output .navbox-abovebelow,.mw-parser-output .navbox-group,.mw-parser-output .navbox-subgroup .navbox-title{background-color:#ddf}.mw-parser-output .navbox-subgroup .navbox-group,.mw-parser-output .navbox-subgroup .navbox-abovebelow{background-color:#e6e6ff}.mw-parser-output .navbox-even{background-color:#f7f7f7}.mw-parser-output .navbox-odd{background-color:transparent}.mw-parser-output .navbox .hlist td dl,.mw-parser-output .navbox .hlist td ol,.mw-parser-output .navbox .hlist td ul,.mw-parser-output .navbox td.hlist dl,.mw-parser-output .navbox td.hlist ol,.mw-parser-output .navbox td.hlist ul{padding:0.125em 0}.mw-parser-output .navbox .navbar{display:block;font-size:100%}.mw-parser-output .navbox-title .navbar{float:left;text-align:left;margin-right:0.5em}.mw-parser-output .navbar{display:inline;font-size:88%;font-weight:normal}.mw-parser-output .navbar-collapse{float:left;text-align:left}.mw-parser-output .navbar-boxtext{word-spacing:0}.mw-parser-output .navbar ul{display:inline-block;white-space:nowrap;line-height:inherit}.mw-parser-output .navbar-brackets::before{margin-right:-0.125em;content:"[ "}.mw-parser-output .navbar-brackets::after{margin-left:-0.125em;content:" ]"}.mw-parser-output .navbar li{word-spacing:-0.125em}.mw-parser-output .navbar a>span,.mw-parser-output .navbar a>abbr{text-decoration:inherit}.mw-parser-output .navbar-mini abbr{font-variant:small-caps;border-bottom:none;text-decoration:none;cursor:inherit}.mw-parser-output .navbar-ct-full{font-size:114%;margin:0 7em}.mw-parser-output .navbar-ct-mini{font-size:114%;margin:0 4em}vteMajor chemical drug groups – based upon the Anatomical Therapeutic Chemical Classification Systemgastrointestinal tract/ metabolism (A)
stomach acid
Antacids
H2 antagonists
Proton-pump inhibitors
Antiemetics
Laxatives
Antidiarrhoeals / Antipropulsives
Anti-obesity drugs
Diabetes medication
Vitamins
Dietary minerals
blood and bloodforming organs (B)
Antithrombotics
Antiplatelets
Anticoagulants
Thrombolytics / fibrinolytics
Antihemorrhagics
Platelets
Coagulants
Antifibrinolytics
cardiovascularsystem (C)
cardiac therapy / antianginals
Cardiac glycosides
Antiarrhythmics
Cardiac stimulants
Antihypertensives
Diuretics
Vasodilators
Beta blockers
Calcium channel blockers
renin–angiotensin system
ACE inhibitors
Angiotensin II receptor antagonists
Renin inhibitors
Antihyperlipidemics
Statins
Fibrates
Bile acid sequestrants
skin (D)
Emollients
Cicatrizants
Antipruritics
Antipsoriatics
Medicated dressings
genitourinarysystem (G)
Hormonal contraception
Fertility agents
Selective estrogen receptor modulators
Sex hormones
endocrinesystem (H)
Hypothalamic–pituitary hormones
Corticosteroids
Glucocorticoids
Mineralocorticoids
Sex hormones
Thyroid hormones / Antithyroid agents
infections andinfestations (J, P, QI)
Antimicrobials: Antibacterials (Antimycobacterials)
Antifungals
Antivirals
Antiparasitics
Antiprotozoals
Anthelmintics
Ectoparasiticides
Intravenous immunoglobulin
Vaccines
malignant disease(L01–L02)
Anticancer agents
Antimetabolites
Alkylating
Spindle poisons
Antineoplastic
Topoisomerase inhibitors
immune disease(L03–L04)
Immunomodulators
Immunostimulants
Immunosuppressants
muscles, bones,and joints (M)
Anabolic steroids
Anti-inflammatories
Non-steroidal anti-inflammatory drugs
Antirheumatics
Corticosteroids
Muscle relaxants
Bisphosphonates
brain andnervous system (N)
Analgesics
Anesthetics
General
Local
Anorectics
Anti-ADHD agents
Antiaddictives
Anticonvulsants
Antidementia agents
Antidepressants
Antimigraine agents
Antiparkinson agents
Antipsychotics
Anxiolytics
Aphrodisiacs
Depressants
Entactogens
Entheogens
Euphoriants
Hallucinogens
Psychedelics
Dissociatives
Deliriants
Hypnotics / Sedatives
Mood stabilizers
Neuroprotectives
Nootropics
Neurotoxins
Orexigenics
Serenics
Stimulants
Wakefulness-promoting agents
respiratorysystem (R)
Decongestants
Bronchodilators
Cough medicines
H1 antagonists
sensory organs (S)
Ophthalmologicals
Otologicals
other ATC (V)
Antidotes
Contrast media
Radiopharmaceuticals
Dressings
Senotherapeutics

 Drugs
Pharmacological classification systems
ATC codes
 Medicine portal

vteRecreational drug useMajor recreational drugsDepressants
Barbiturates
Benzodiazepines
Carbamates
Ethanol (alcohol)
Alcoholic drinks
Beer
Wine
Gabapentinoids
GHB
Inhalants
Medical
Nitrous oxide (recreational use)
Hazardous solvents
contact adhesives
Gasoline
nail polish remover
Paint thinner
Other
Freon
Kava
Nonbenzodiazepines
Quinazolinones
Opioids
Buprenorphine
Suboxone
Subutex
Codeine
Desomorphine
Krokodil
Dextropropoxyphene
Darvocet
Darvon
Fentanyl
Diamorphine
Heroin
Hydrocodone
Hydromorphone
Dilaudid
Methadone
Mitragyna speciosa
Kratom
Morphine
Opium
Oxycodone
/paracetamol
Tramadol
Stimulants
Amphetamine
Arecoline
Areca
Betel
Caffeine
Coffee
Energy drinks
Tea
Cathinone
Khat
Cocaine
Coca
Crack
Ephedrine
Ephedra
MDPV
Mephedrone
Methamphetamine
Methylone
Methylphenidate
Modafinil
Nicotine
Tobacco
Theobromine
Cocoa
Chocolate
Entactogens
2C series
6-APB
Benzofury
AMT
MDA
MDMA
Ecstasy
HallucinogensPsychedelics
Bufotenin
Psychoactive toads
Vilca
Yopo
DMT
Ayahuasca
LSA
LSD-25
Mescaline
Peruvian torch
Peyote
San Pedro
Psilocybin / Psilocin
Psilocybin mushrooms
Dissociatives
DXM (recreational use)
Glaucine
Inhalants
Nitrous oxide (recreational use)
alkyl nitrites
poppers
amyl nitrite
Ketamine
MXE
Muscimol
Amanita muscaria
PCP
Salvinorin A
Salvia divinorum
Deliriants
Atropine and Scopolamine
Atropa belladonna
Datura
Hyoscyamus niger
Mandragora officinarum
Dimenhydrinate
Diphenhydramine
Cannabinoids
THC
Cannabis (Marijuana)
Hashish
Hash oil
Neocannabinoid / synthetic cannabinoids
JWH-018
APICA
APINACA
Spice
Oneirogens
Calea zacatechichi
Silene capensis
Club drugs
Cocaine
Quaaludes
MDMA (Ecstasy)
Nitrous oxide (recreational use)
Poppers
Drug cultureCannabis culture
420
Cannabis cultivation
Cannabis rights leaders
Cannabis smoking
Cannabis Social Club
Head shop
Legal history of cannabis in the United States
Legality of cannabis
Marijuana Policy Project
Medical cannabis
NORML
Cannabis and religion
Stoner film
Coffee culture
Coffee break
Coffeehouse
Latte art
Teahouse
Drinking culture
Bartending
Beer culture
Beer festival
Binge drinking
Diethyl ether
Drinking games
Drinking song
Happy hour
Hip flask
Nightclub
Pub
Pub crawl
Sommelier
Sports bar
Tailgate party
Wine bar
Wine tasting
Psychedelia
Psychonautics
Art
Drug
Era
Experience
Literature
Music
Microdosing
Therapy
Smoking culture
Cigarette card
Fashion cigarettes
Cloud-chasing
Loosie
Smokeasy
Smoking fetishism
Tobacco smoking
Other
Club drug
Counterculture of the 1960s
Dance party
Drug paraphernalia
Drug tourism
Entheogen
Hippie
Needle sharing
Nootropic
Party and play
Poly drug use
Rave
Religion and drugs
Self-medication
Sex and drugs
Whoonga
Drug production and tradeDrug production
Coca production in Colombia
Drug precursors
Opium production in Afghanistan
Rolling meth lab
Drug trade
Illegal drug trade
Colombia
Darknet market
Pharmaceutical distribution
Beer shop
Cannabis shop
Liquor store
Liquor license
Issues with drug use
Abuse
Addiction
Date rape drug
Dependence
Opioid replacement therapy
Prevention
Rehabilitation
Responsible use
Driving impaired
Drug checking
Reagent testing
Drug harmfulness
Effects of cannabis
Drug-related crime
Fetal alcohol spectrum disorder
Long-term effects of cannabis
Neurotoxicity
Overdose
Passive smoking
of tobacco or other substances
Legality of drug useInternational
International Drug Control Conventions
1961 Narcotic Drugs
1971 Psychotropic Substances
1988 Drug Trafficking
Other treaties addressing drugs
Law of the Sea Convention
Convention Against Doping
Council of the European Union decisions on designer drugs
State level
Drug policy
Decriminalization
Prohibition
Supply reduction
Policy reform
Demand reduction
Drug Policy Alliance
Harm reduction
Law Enforcement Action Partnership
Liberalization
Latin America
Students for Sensible Drug Policy
Transform Drug Policy Foundation
Drug policyby country
Australia
Canada
Germany
India
Netherlands
Portugal
Slovakia
Soviet Union
Sweden
Switzerland
United States
Just Say No
Office of National Drug Control Policy
School district drug policies
California
Colorado
Maryland
Virginia
Other
Arguments for and against drug prohibition
Capital punishment for drug trafficking
Cognitive liberty
Designer drug
Drug court
Drug possession
Drug test
Narc
Politics of drug abuse
War on drugs
Mexican drug war
Plan Colombia
Philippine drug war
Zero tolerance
Lists of countries by...
Alcohol legality
Alcohol consumption
Anabolic steroid legality
Cannabis legality
Annual use
Lifetime use
Tobacco consumption
Cocaine legality
Cocaine use
Methamphetamine legality
Opiates use
Psilocybin mushrooms legality
Salvia legality

vteHallucinogensPsychedelics(5-HT2Aagonists)Benzofurans
2C-B-FLY
2CBFly-NBOMe
5-MeO-BFE
5-MeO-DiBF
Bromo-DragonFLY
F-2
F-22
TFMFly
Lyserg‐amides
1B-LSD
1cP-LSD
1P-ETH-LAD
1P-LSD
1cP-AL-LAD
1cP-MiPLA
1V-LSD
2-Butyllysergamide
3-Pentyllysergamide
AL-LAD
ALD-52
BU-LAD
Diallyllysergamide
Dimethyllysergamide
ECPLA
Ergometrine
ETH-LAD
IP-LAD
LAE-32
LAMPA
LPD-824
LSA
LSD
LSD-Pip
LSH
LSM-775
LSZ
Methylergometrine
MIPLA
Methysergide
MLD-41
PARGY-LAD
PRO-LAD
Phenethyl‐amines2C-x
2C-B
2C-B-AN
2C-Bn
2C-Bu
2C-C
2C-CN
2C-CP
2C-D
2C-E
2C-EF
2C-F
2C-G
2C-G-1
2C-G-2
2C-G-3
2C-G-4
2C-G-5
2C-G-6
2C-G-N
2C-H
2C-I
2C-iP
2C-N
2C-NH2
2C-O
2C-O-4
2C-P
2C-Ph
2C-SE
2C-T
2C-T-2
2C-T-3
2C-T-4
2C-T-5
2C-T-6
2C-T-7
2C-T-8
2C-T-9
2C-T-10
2C-T-11
2C-T-12
2C-T-13
2C-T-14
2C-T-15
2C-T-16
2C-T-17
2C-T-18
2C-T-19
2C-T-20
2C-T-21
2C-T-22
2C-T-22.5
2C-T-23
2C-T-24
2C-T-25
2C-T-27
2C-T-28
2C-T-30
2C-T-31
2C-T-32
2C-T-33
2C-TFE
2C-TFM
2C-YN
2C-V
    25x-NBx25x-NB
25B-NB
25C-NB
25x-NB3OMe
25B-NB3OMe
25C-NB3OMe
25D-NB3OMe
25E-NB3OMe
25H-NB3OMe
25I-NB3OMe
25N-NB3OMe
25P-NB3OMe
25T2-NB3OMe
25T4-NB3OMe
25T7-NB3OMe
25TFM-NB3OMe
25x-NB4OMe
25B-NB4OMe
25C-NB4OMe
25D-NB4OMe
25E-NB4OMe
25H-NB4OMe
25I-NB4OMe
25N-NB4OMe
25P-NB4OMe
25T2-NB4OMe
25T4-NB4OMe
25T7-NB4OMe
25TFM-NB4OMe
25x-NBF
25B-NBF
25C-NBF
25D-NBF
25E-NBF
25H-NBF
25I-NBF
25P-NBF
25T2-NBF
25T7-NBF
25TFM-NBF
25x-NBMD
25B-NBMD
25C-NBMD
25D-NBMD
25E-NBMD
25F-NBMD
25H-NBMD
25I-NBMD
25P-NBMD
25T2-NBMD
25T7-NBMD
25TFM-NBMD
25x-NBOH
25B-NBOH
25C-NBOH
25CN-NBOH
25D-NBOH
25E-NBOH
25F-NBOH
25H-NBOH
25I-NBOH
25P-NBOH
25T2-NBOH
25T7-NBOH
25TFM-NBOH
25x-NBOMe
25B-NBOMe
25C-NBOMe
25CN-NBOMe
25D-NBOMe
25E-NBOMe
25F-NBOMe
25G-NBOMe
25H-NBOMe
25I-NBOMe
25iP-NBOMe
25N-NBOMe
25P-NBOMe
25T-NBOMe
25T2-NBOMe
25T4-NBOMe
25T7-NBOMe
25TFM-NBOMe
Atypical structures
25B-N1POMe
25B-NAcPip
25B-NB23DM
25B-NB25DM
25C-NBCl
25C-NBOEt
25C-NBOiPr
25I-N2Nap1OH
25I-N3MT2M
25I-N4MT3M
25I-NB34MD
25I-NBAm
25I-NBBr
25I-NBMeOH
25I-NBTFM
2CBCB-NBOMe
2CBFly-NBOMe
4-EA-NBOMe
5-APB-NBOMe
5MT-NBOMe
C30-NBOMe
DOB-NBOMe
DOI-NBOMe
FECIMBI-36
MDPEA-NBOMe
NBOMe-escaline
NBOMe-mescaline
ZDCM-04
25x-NMx
25B-NMe7BF
25B-NMe7BT
25B-NMe7Box
25B-NMe7DHBF
25B-NMe7Ind
25B-NMe7Indz
25B-NMePyr
25I-NMe7DHBF
25I-NMeFur
25I-NMeTHF
25I-NMeTh

3C-x
3C-AL
3C-BZ
3C-DFE
3C-E
3C-MAL
3C-P
4C-x
4C-B
4C-C
4C-D
4C-E
4C-I
4C-N
4C-P
4C-T-2
DOx
DOT
DOB
DOC
DOEF
DOET
DOF
DOI
DOiPR
DOM
DON
DOPR
DOTFM
MEM
HOT-x
HOT-2
HOT-7
HOT-17
MDxx
DMMDA
DMMDA-2
Lophophine
MDA
MDAI
MDBZ
MDMA
MMDA
MMDA-2
MMDA-3a
MMDMA
Mescaline (subst.)
2-Bromomescaline
3-TE
4-TE
3-TM
4-TM
Allylescaline
Asymbescaline
Buscaline
Cyclopropylmescaline
Difluoromescaline
Difluoroescaline
Escaline
Fluoroproscaline
Isobuscaline
Isoproscaline
Jimscaline
Mescaline
Metaescaline
Methallylescaline
Proscaline
Thioproscaline
Trifluoroescaline
Trifluoromescaline
TMAs
TMA
TMA-2
TMA-3
TMA-4
TMA-5
TMA-6
Others
2C-B-BUTTERFLY
2C-B-DragonFLY
2C-B-DragonFLY-NBOH
2C-B-FLY-NB2EtO5Cl
2CB-5-hemifly
2CB-Ind
2CD-5EtO
2-TOET
5-TOET
2-TOM
5-TOM
BOB
BOD
βk-2C-B
βk-2C-I
DESOXY
DMCPA
DMBMPP
DOB-FLY
Fenfluramine
Ganesha
Macromerine
MMA
TCB-2
TOMSO
Piperazines
2C-B-PP
BZP
pFPP
Tryptaminesalpha-alkyltryptamines
4,5-DHP-α-MT
5-MeO-α-ET
5-MeO-α-MT
α-ET
α-MT
x-DALT
(Daltocin) 4-HO-DALT
(Daltacetin) 4-AcO-DALT
5-MeO-DALT
DALT
x-DET
(Ethacetin) 4-AcO-DET
(Ethocin) 4-HO-DET
5-MeO-DET
(T-9) DET
(Ethocybin) 4-PO-DET
x-DiPT
(Ipracetin) 4-AcO-DiPT
(Iprocin) 4-HO-DiPT
5-MeO-DiPT
DiPT
x-DMT
4,5-DHP-DMT
2,N,N-TMT
4-AcO-DMT
4-HO-5-MeO-DMT
4,N,N-TMT
4-Propionyloxy-DMT
5,6-diBr-DMT
5-AcO-DMT
5-Bromo-DMT
5-MeO-2,N,N-TMT
5-MeO-4,N,N-TMT
5-MeO-α,N,N-TMT
5-MeO-DMT
5-N,N-TMT
7,N,N-TMT
α,N,N-TMT
(Bufotenin) 5-HO-DMT
DMT
Norbaeocystin
(Psilocin) 4-HO-DMT
(Psilocybin) 4-PO-DMT
x-DPT
(Depracetin) 4-AcO-DPT
(Deprocin) 4-HO-DPT
5-MeO-DPT
(The Light) DPT
Ibogaine-related
18-MAC
18-MC
Coronaridine
Ibogaine
Ibogamine
ME-18-MC
Noribogaine
Tabernanthine
Voacangine
x-MET
(Metocin) 4-HO-MET
(Metocetin) 4-AcO-MET
5-MeO-MET
MET
x-MiPT
(Mipracetin) 4-AcO-MiPT
(Miprocin) 4-HO-MiPT
5-Me-MiPT
(Moxy) 5-MeO-MiPT
MiPT
Others
4-HO-DBT
4-HO-EPT
4-HO-McPT
(Lucigenol) 4-HO-MPMI
(Meprocin) 4-HO-MPT
5-MeO-EiPT
5-MeO-MALT
5-MeO-MPMI
Aeruginascin
Baeocystin
DBT
DCPT
EiPT
EPT
MPT
PiPT
Others
AL-38022A
ALPHA
Dimemebfe
Efavirenz
Glaucine
Lorcaserin
M-ALPHA
RH-34Also empathogens in general (e. g.: 5-APB, 5-MAPB, 6-APB and other substituted benzofurans).
Dissociatives(NMDARantagonists)Arylcyclo‐hexylaminesKetamine-related
2-Fluorodeschloroketamine
Arketamine ((R)-ketamine)
Deschloroketamine
Ethketamine (N-Ethylnorketamine)
Esketamine ((S)-ketamine)
Ketamine
Methoxetamine
Methoxmetamine
Methoxyketamine
MXiPr
Norketamine
Tiletamine
PCP-related
2'-Oxo-PCE
3-HO-PCP
3-MeO-PCE
3-MeO-PCMo
3-MeO-PCP
4-MeO-PCP
BDPC
Dieticyclidine (PCDE)
Eticyclidine (PCE)
PCPr
Phencyclidine (PCP)
Rolicyclidine (PCPy)
Tenocyclidine (TCP)
Others
BTCP
Gacyclidine
PRE-084
Diarylethylamines
Diphenidine
Ephenidine
Fluorolintane
Methoxphenidine
Morphinans
Dextrallorphan
Dextromethorphan
Dextrorphan
Racemethorphan
Racemorphan
Others
2-EMSB
2-MDP
8A-PDHQ
Aptiganel
Budipine
Delucemine
Dexoxadrol
Dizocilpine
Etoxadrol
Herkinorin
Ibogaine
Midafotel
NEFA
Neramexane
Nitrous oxide
Noribogaine
Perzinfotel
RB-64
Remacemide
Selfotel
Xenon
Deliriants(mAChRantagonists)
Atropine
Benactyzine
Benzatropine
Benzydamine
Biperiden
BRN-1484501
Brompheniramine
BZ
CAR-226,086
CAR-301,060
CAR-302,196
CAR-302,282
CAR-302,368
CAR-302,537
CAR-302,668
Chloropyramine
Chlorphenamine
Clemastine
CS-27349
Cyclizine
Cyproheptadine
Dicycloverine
Dimenhydrinate
Diphenhydramine
Ditran
Doxylamine
EA-3167
EA-3443
EA-3580
EA-3834
Elemicin
Flavoxate
Hyoscyamine
JB-318
JB-336
Meclozine
Mepyramine
Myristicin
Orphenadrine
Oxybutynin
Pheniramine
Phenyltoloxamine
Procyclidine
Promethazine
Scopolamine
Tolterodine
Trihexyphenidyl
Tripelennamine
Triprolidine
WIN-2299
OthersCannabinoids(CB1 agonists)Natural
Salvinorin A
THC (Dronabinol)
THCV
SyntheticAM-x
AM-087
AM-251
AM-279
AM-281
AM-356
AM-374
AM-381
AM-404
AM-411
AM-630
AM-661
AM-678
AM-679
AM-694
AM-735
AM-855
AM-881
AM-883
AM-905
AM-906
AM-919
AM-926
AM-938
AM-1116
AM-1172
AM-1220
AM-1221
AM-1235
AM-1241
AM-1248
AM-1710
AM-1714
AM-1902
AM-2201
AM-2212
AM-2213
AM-2232
AM-2233
AM-2389
AM-3102
AM-4030
AM-4054
AM-4056
AM-4113
AM-6545
CP x
CP 47,497
CP 55,244
CP 55,940
(±)-CP 55,940
(+)-CP 55,940
(-)-CP 55,940
HU-x
HU-210
HU-211
HU-239
HU-243
HU-308
HU-320
HU-331
HU-336
HU-345
JWH-x
JWH-007
JWH-015
JWH-018
JWH-019
JWH-030
JWH-047
JWH-048
JWH-051
JWH-057
JWH-073
JWH-081
JWH-098
JWH-116
JWH-120
JWH-122
JWH-133
JWH-139
JWH-147
JWH-148
JWH-149
JWH-149
JWH-161
JWH-164
JWH-166
JWH-167
JWH-171
JWH-175
JWH-176
JWH-181
JWH-182
JWH-184
JWH-185
JWH-192
JWH-193
JWH-194
JWH-195
JWH-196
JWH-197
JWH-198
JWH-199
JWH-200
JWH-203
JWH-205
JWH-210
JWH-210
JWH-213
JWH-220
JWH-229
JWH-234
JWH-249
JWH-250
JWH-251
JWH-253
JWH-258
JWH-300
JWH-302
JWH-307
JWH-336
JWH-350
JWH-359
JWH-387
JWH-398
JWH-424
Misc. designer cannabinoids
4-HTMPIPO
5F-AB-FUPPYCA
5F-AB-PINACA
5F-ADB
5F-ADB-PINACA
5F-ADBICA
5F-AMB
5F-APINACA
5F-CUMYL-PINACA
5F-NNE1
5F-PB-22
5F-SDB-006
A-796,260
A-836,339
AB-001
AB-005
AB-CHFUPYCA
AB-CHMINACA
AB-FUBINACA
AB-PINACA
ADAMANTYL-THPINACA
ADB-CHMINACA
ADB-FUBINACA
ADB-PINACA
ADBICA
ADSB-FUB-187
AMB-FUBINACA
APICA
APINACA
APP-FUBINACA
CB-13
CUMYL-PICA
CUMYL-PINACA
CUMYL-THPINACA
DMHP
EAM-2201
FAB-144
FDU-PB-22
FUB-144
FUB-APINACA
FUB-JWH-018
FUB-PB-22
FUBIMINA
JTE 7-31
JTE-907
Levonantradol
MDMB-CHMICA
MDMB-CHMINACA
MDMB-FUBINACA
MEPIRAPIM
MAM-2201
MDA-19
MN-18
MN-25
NESS-0327
NESS-040C5
Nabilone
Nabitan
NM-2201
NNE1
Org 28611
Parahexyl
PTI-1
PTI-2
PX-1
PX-2
PX-3
QUCHIC
QUPIC
RCS-4
RCS-8
SDB-005
SDB-006
STS-135
THC-O-acetate
THC-O-phosphate
THJ-018
THJ-2201
UR-144
WIN 55,212-2
XLR-11
D2 agonists
Apomorphine
Aporphine
Bromocriptine
Cabergoline
Lisuride
LSD
Memantine
Nuciferine
Pergolide
Phenethylamine
Piribedil
Pramipexole
Ropinirole
Rotigotine
Salvinorin AAlso indirect D2 agonists, such as dopamine reuptake inhibitors (cocaine, methylphenidate), releasing agents (amphetamine, methamphetamine), and precursors (levodopa).
GABAAenhancers
CI-966
Eszopiclone
Ibotenic acid
Muscimol (Amanita muscaria)
Zaleplon
Zolpidem
Zopiclone
Inhalants(Mixed MOA)
Aliphatic hydrocarbons
Butane
Gasoline
Kerosene
Propane
Aromatic hydrocarbons
Toluene
Ethers
Diethyl ether
Enflurane
Haloalkanes
Chlorofluorocarbons
Chloroform
κOR agonists
2-EMSB
Alazocine
Bremazocine
Butorphan
Butorphanol
Cyclazocine
Cyclorphan
Cyprenorphine
Diprenorphine
Enadoline
Herkinorin
Heroin
HZ-2
Ibogaine
Ketazocine
Levallorphan
Levomethorphan
Levorphanol
LPK-26
Metazocine
Morphine
Nalbuphine
Nalmefene
Nalorphine
Noribogaine
Oxilorphan
Pentazocine
Phenazocine
Proxorphan
Racemethorphan
Racemorphan
Salvinorin A
Spiradoline
Tifluadom
U-50488
U-69,593
Xorphanol
Oneirogens
Calea zacatechichi
Silene capensis
Galantamine
Others
Glaucine
Isoaminile
Noscapine
Pukateine






